EP2672967A4 - COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF - Google Patents

COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF

Info

Publication number: EP2672967A4
Authority: EP; European Patent Office
Prior art keywords: indications; compounds; methods; modulating kinase; kinase
Prior art date: 2011-02-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP12745360.3A

Other languages

German (de)

French (fr)

Other versions

EP2672967A1 (en

EP2672967B1 (en

Inventor

Prabha N Ibrahim

Chao Zhang

Wayne Spevak

Jiazhong Zhang

Guoxian Wu

Jack Lin

Hanna Cho

Marika Nespi

Songyuan Shi

Todd Ewing

Ying Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Plexxikon Inc

Original Assignee

Plexxikon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-07

Filing date

2012-02-01

Publication date

2014-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2672967(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-02-01 Priority to RS20181464A priority Critical patent/RS58455B1/en

2012-02-01 Priority to SM20190112T priority patent/SMT201900112T1/en

2012-02-01 Priority to HRP20181779TT priority patent/HRP20181779T1/en

2012-02-01 Priority to PL12745360T priority patent/PL2672967T3/en

2012-02-01 Priority to SI201231458T priority patent/SI2672967T1/en

2012-02-01 Application filed by Plexxikon Inc filed Critical Plexxikon Inc

2013-12-18 Publication of EP2672967A1 publication Critical patent/EP2672967A1/en

2014-08-20 Publication of EP2672967A4 publication Critical patent/EP2672967A4/en

2018-10-17 Publication of EP2672967B1 publication Critical patent/EP2672967B1/en

2018-10-17 Application granted granted Critical

Status Active legal-status Critical Current

2032-02-01 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Virology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Emergency Medicine (AREA)

EP12745360.3A 2011-02-07 2012-02-01 Compounds and methods for kinase modulation, and indications therefor Active EP2672967B1 (en)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
SM20190112T SMT201900112T1 (en)	2011-02-07	2012-02-01	Compounds and methods for kinase modulation, and indications therefor
HRP20181779TT HRP20181779T1 (en)	2011-02-07	2012-02-01	COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS FOR THEM
PL12745360T PL2672967T3 (en)	2011-02-07	2012-02-01	Compounds and methods for kinase modulation, and indications therefor
SI201231458T SI2672967T1 (en)	2011-02-07	2012-02-01	Compounds and methods for kinase modulation, and indications therefor
RS20181464A RS58455B1 (en)	2011-02-07	2012-02-01	Compounds and methods for kinase modulation, and indications therefor

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161440339P	2011-02-07	2011-02-07
PCT/US2012/023543 WO2012109075A1 (en)	2011-02-07	2012-02-01	Compounds and methods for kinase modulation, and indications therefor

Publications (3)

Publication Number	Publication Date
EP2672967A1 EP2672967A1 (en)	2013-12-18
EP2672967A4 true EP2672967A4 (en)	2014-08-20
EP2672967B1 EP2672967B1 (en)	2018-10-17

Family

ID=46638904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP12745360.3A Active EP2672967B1 (en)	2011-02-07	2012-02-01	Compounds and methods for kinase modulation, and indications therefor

Country Status (37)

Country	Link
US (4)	US9624213B2 (en)
EP (1)	EP2672967B1 (en)
JP (3)	JP5941069B2 (en)
KR (1)	KR101911972B1 (en)
CN (1)	CN103517710B (en)
AR (1)	AR085316A1 (en)
AU (1)	AU2012214762B2 (en)
BR (1)	BR112013020041B1 (en)
CA (1)	CA2826123C (en)
CL (1)	CL2013002228A1 (en)
CO (1)	CO6781514A2 (en)
CR (1)	CR20130374A (en)
CY (1)	CY1121511T1 (en)
DK (1)	DK2672967T3 (en)
EA (1)	EA028821B9 (en)
EC (1)	ECSP13012869A (en)
ES (1)	ES2696023T3 (en)
HR (1)	HRP20181779T1 (en)
HU (1)	HUE040136T2 (en)
IL (1)	IL227698B (en)
LT (1)	LT2672967T (en)
MA (1)	MA34948B1 (en)
MX (1)	MX358128B (en)
MY (1)	MY162950A (en)
PE (1)	PE20141360A1 (en)
PH (1)	PH12013501633B1 (en)
PL (1)	PL2672967T3 (en)
PT (1)	PT2672967T (en)
RS (1)	RS58455B1 (en)
SG (1)	SG192686A1 (en)
SI (1)	SI2672967T1 (en)
SM (1)	SMT201900112T1 (en)
TR (1)	TR201816421T4 (en)
TW (1)	TWI640521B (en)
UY (1)	UY33899A (en)
WO (1)	WO2012109075A1 (en)
ZA (1)	ZA201305856B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
SG183036A1 (en)	2007-07-17	2012-08-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en)	2008-05-19	2009-11-26	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
CN102361870B (en)	2009-04-03	2015-11-25	豪夫迈罗氏公司	Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}- Amide compositions and uses thereof
AR077468A1 (en)	2009-07-09	2011-08-31	Array Biopharma Inc	PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
MX2012005284A (en)	2009-11-06	2012-06-28	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor.
BR112012011792A2 (en)	2009-11-18	2015-10-13	Plexxikon Inc	"compounds and methods for modulating kinases, and indications thereof"
CA2784393A1 (en)	2009-12-23	2011-06-30	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
TWI619713B (en)	2010-04-21	2018-04-01	普雷辛肯公司	Compounds and methods for kinase regulation and their indications
JP5941069B2 (en)	2011-02-07	2016-06-29	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	Compounds and methods for kinase regulation and indications therefor
CN103917235A (en)	2011-05-17	2014-07-09	普莱希科公司	Kinase modulation and indications therefor
WO2013086260A2 (en) *	2011-12-09	2013-06-13	Oncomed Pharmaceuticals, Inc.	Combination therapy for treatment of cancer
US9358235B2 (en)	2012-03-19	2016-06-07	Plexxikon Inc.	Kinase modulation, and indications therefor
WO2013142817A2 (en)	2012-03-23	2013-09-26	Dennis Brown	Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
TWI601725B (en)	2012-08-27	2017-10-11	加拓科學公司	Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
CA2883894C (en)	2012-09-06	2020-08-18	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
RS57117B1 (en)	2012-12-21	2018-06-29	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
SG11201506687RA (en)	2013-03-15	2015-09-29	Plexxikon Inc	Heterocyclic compounds and uses thereof
US20140303121A1 (en)	2013-03-15	2014-10-09	Plexxikon Inc.	Heterocyclic compounds and uses thereof
RU2015149937A (en)	2013-05-30	2017-07-06	Плексксикон Инк.	COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
WO2015134536A1 (en)	2014-03-04	2015-09-11	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
UY36294A (en)	2014-09-12	2016-04-29	Novartis Ag	COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
JP6832846B2 (en)	2014-09-15	2021-02-24	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	Heterocyclic compounds and their uses
WO2016164641A1 (en)	2015-04-08	2016-10-13	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
CN107531706A (en)	2015-05-06	2018-01-02	普莱希科公司	Synthesis of Kinase-Regulating 1H-Pyrrolo[2,3-b]pyridine Derivatives
MX386963B (en)	2015-05-06	2025-03-19	Daiichi Sankyo Inc	SOLID FORMS OF KINASES THAT MODULATE A COMPOUND.
ES2825202T3 (en) *	2015-05-22	2021-05-14	Plexxikon Inc	Synthesis of heterocyclic compounds
CA2986739C (en) *	2015-05-22	2023-03-14	Plexxikon Inc.	Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
KR20180041135A (en)	2015-07-16	2018-04-23	어레이 바이오파마 인크.	A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor
WO2017019804A2 (en)	2015-07-28	2017-02-02	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
MY195977A (en)	2015-09-21	2023-02-27	Plexxikon Inc	Heterocyclic Compounds and uses Thereof
US9890163B2 (en) *	2015-10-15	2018-02-13	Princeton Drug Discovery Inc	Inhibitors of protein kinases
AU2016344058A1 (en)	2015-10-26	2018-05-17	Array Biopharma Inc.	Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
SG11201804711RA (en)	2015-12-07	2018-07-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US10160747B2 (en)	2016-03-16	2018-12-25	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
CN109414442B (en)	2016-04-04	2024-03-29	洛克索肿瘤学股份有限公司	Liquid preparation of compound
SG11201808676RA (en)	2016-04-04	2018-11-29	Loxo Oncology Inc	Methods of treating pediatric cancers
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
US11214571B2 (en)	2016-05-18	2022-01-04	Array Biopharma Inc.	Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
RU2019108280A (en)	2016-08-24	2020-09-25	Аркьюл, Инк.	AMINOPYRROLOPYRIMIDINONE COMPOUNDS AND METHODS FOR THEIR APPLICATION
AU2017329090B9 (en)	2016-09-19	2019-09-05	Novartis Ag	Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
TW201815766A (en)	2016-09-22	2018-05-01	美商普雷辛肯公司	Compounds and methods for IDO and TDO modulation, and indications therefor
JOP20190077A1 (en)	2016-10-10	2019-04-09	Array Biopharma Inc	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en)	2016-10-26	2019-04-25	Array Biopharma Inc	PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
CN117510491A (en) *	2016-12-23	2024-02-06	阿尔维纳斯运营股份有限公司	Compounds and methods for targeted degradation of rapidly accelerating fibrosarcoma polypeptides
CA3047580A1 (en) *	2016-12-23	2018-07-26	Plexxikon Inc.	Compounds and methods for cdk8 modulation and indications therefor
MX393780B (en)	2017-01-17	2025-03-24	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
CN110267960B (en)	2017-01-18	2022-04-26	阿雷生物药品公司	Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors
JOP20190213A1 (en)	2017-03-16	2019-09-16	Array Biopharma Inc	Macrocyclic compounds as ros1 kinase inhibitors
US10577366B2 (en)	2017-03-20	2020-03-03	Plexxikon Inc.	Crystalline forms of a compound that inhibits bromodomain
KR20240032157A (en)	2017-05-02	2024-03-08	노파르티스 아게	Combination therapy
US10428067B2 (en)	2017-06-07	2019-10-01	Plexxikon Inc.	Compounds and methods for kinase modulation
US10435404B2 (en)	2017-07-25	2019-10-08	Plexxikon Inc.	Formulations of a compound modulating kinases
TWI876442B (en)	2017-10-10	2025-03-11	美商絡速藥業公司	Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
WO2019075243A1 (en)	2017-10-13	2019-04-18	Plexxikon Inc.	Solid forms of a compound for modulating kinases
AU2018354423B2 (en) *	2017-10-27	2024-11-07	Plexxikon Inc.	Formulations of a compound modulating kinases
US11603374B2 (en)	2018-01-18	2023-03-14	Array Biopharma Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
TW201932464A (en)	2018-01-18	2019-08-16	美商亞雷生物製藥股份有限公司	Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
ES3000465T3 (en)	2018-01-31	2025-02-28	Heparegenix Gmbh	Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3094336A1 (en)	2018-03-20	2019-09-26	Plexxikon Inc.	Compounds and methods for ido and tdo modulation, and indications therefor
RU2687107C1 (en) *	2018-06-18	2019-05-07	федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)"	Braf kinase inhibitor n-(3-(5-(4-chlorophenyl)-1h-pyrazolo[3,4-b]pyridin-3-carbonil)-2,4-difluorophenyl)propane-1-sulfonamide
US11731968B2 (en)	2018-06-21	2023-08-22	Heparegenix Gmbh	Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112424201B (en)	2018-07-16	2024-04-02	海帕瑞吉尼克斯股份有限公司	Protein kinase inhibitors that promote liver regeneration or reduce or prevent liver cell death
EP3829543A1 (en)	2018-07-31	2021-06-09	Loxo Oncology, Inc.	Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
WO2020055672A1 (en)	2018-09-10	2020-03-19	Array Biopharma Inc.	Fused heterocyclic compounds as ret kinase inhibitors
US12351571B2 (en)	2018-12-19	2025-07-08	Array Biopharma Inc.	Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
US12180207B2 (en)	2018-12-19	2024-12-31	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
CN111434661B (en) *	2019-01-11	2023-09-12	爱科诺生物医药(香港)有限公司	Aromatic heterocyclic compound with cell necrosis inhibition activity and application thereof
TW202444718A (en) *	2019-01-25	2024-11-16	英屬開曼群島商百濟神州有限公司	Compound as b-raf kinase dimer inhibitor and preparation method thereof
JP7636646B2 (en)	2019-04-09	2025-02-27	オプナバイオソシエテアノニム	Condensed azines and their applications for the modulation of EP300 or CBP
AU2020257262A1 (en)	2019-04-18	2021-11-18	Brown University	Neurogenesis
WO2020215057A1 (en) *	2019-04-18	2020-10-22	The Regents Of The University Of California	Pharmacological mitigation of late-stage toxemia
CN113795490A (en)	2019-05-13	2021-12-14	诺华股份有限公司	Novel crystalline forms of N- (3- (2- (2-hydroxyethoxy) -6-morpholinopyridin-4-yl) -4-methylphenyl) -2 (trifluoromethyl) isonicotinamide as Raf inhibitors for the treatment of cancer
KR102878355B1 (en)	2019-07-29	2025-10-28	헤파레게닉스 게엠베하	Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte apoptosis
CN110889859A (en) *	2019-11-11	2020-03-17	珠海上工医信科技有限公司	U-shaped network for fundus image blood vessel segmentation
US20230101747A1 (en)	2019-12-06	2023-03-30	Schrödinger, Inc.	Cyclic compounds and methods of using same
CR20220252A (en) *	2019-12-10	2022-07-11	Hoffmann La Roche	New braf inhibitors as paradox breakers
EP4077316A1 (en)	2019-12-20	2022-10-26	Pfizer Inc.	Benzimidazole derivatives
CA3161339A1 (en)	2019-12-27	2021-07-01	Schrodinger, Inc.	Cyclic compounds and methods of using same
AU2021207236A1 (en)	2020-01-15	2022-08-11	Heparegenix Gmbh	3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases
AU2021261383A1 (en)	2020-04-23	2022-11-17	Opna Bio SA	Compounds and methods for CD73 modulation and indications therefor
CN115605460A (en)	2020-04-29	2023-01-13	普莱希科公司（Us）	Synthesis of Heterocyclic Compounds
TW202227068A (en)	2020-08-21	2022-07-16	美商普雷辛肯公司	Combinational drug therapies
US20230365584A1 (en)	2020-09-10	2023-11-16	Schrödinger, Inc.	Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
EP4284804A1 (en)	2021-01-26	2023-12-06	Schrödinger, Inc.	Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (en)	2021-03-18	2023-01-01	美商薛定諤公司	Cyclic compounds and methods of using same
WO2025059027A1 (en)	2023-09-11	2025-03-20	Schrödinger, Inc.	Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors

Citations (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007002325A1 (en) *	2005-06-22	2007-01-04	Plexxikon, Inc.	Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008079903A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2, 3-b] pyridine derivatives as kinase modulators
WO2010104945A1 (en) *	2009-03-11	2010-09-16	Plexxikon, Inc.	Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
WO2010129567A1 (en) *	2009-05-06	2010-11-11	Plexxikon, Inc.	Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase
WO2011015522A2 (en) *	2009-08-03	2011-02-10	F. Hoffmann-La Roche Ag	Process for the manufacture of pharmaceutically active compounds
WO2011060216A1 (en) *	2009-11-12	2011-05-19	Concert Pharmaceuticals Inc.	Substituted azaindoles
WO2011063159A1 (en) *	2009-11-18	2011-05-26	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
WO2011079133A2 (en) *	2009-12-23	2011-06-30	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
WO2012037060A1 (en) *	2010-09-13	2012-03-22	Concert Pharmaceuticals Inc.	Substituted azaindoles
WO2012138809A1 (en) *	2011-04-05	2012-10-11	Dawei Zhang	Heterocyclic compounds as kinase inhibitors

Family Cites Families (341)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2234705A (en)	1940-04-12	1941-03-11	Eastman Kodak Co	Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids
US2413258A (en)	1942-07-07	1946-12-24	United Gas Improvement Co	Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters
DE1668420B2 (en)	1966-10-21	1976-11-25	Minnesota Mining and Manufacturing Co., Saint Paul, Minn. (V.StA.)	TRIFLUOROMETHYLSULFONANILIDES, METHOD FOR THEIR MANUFACTURING AND USE
DE2413258A1 (en)	1974-03-20	1975-10-02	Bayer Ag	Herbicidal N-(alkoxycarbonyl-phenyl)-N'-methyl-urea derivs - prepd by reacting alkoxycarbonyl-phenyl isocyanates with methylamines
IL46853A0 (en)	1974-03-20	1975-05-22	Bayer Ag	Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides
GB1573212A (en)	1976-04-15	1980-08-20	Technicon Instr	Immunoassay for gentamicin
US4301159A (en)	1980-06-20	1981-11-17	Shionogi & Co., Ltd.	N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives
AU547405B2 (en)	1981-07-08	1985-10-17	Sanofi	Amidobenzamides
US4664504A (en)	1983-01-20	1987-05-12	Tokyo Shibaura Denki Kabushiki Kaisha	Image forming apparatus
US4568649A (en)	1983-02-22	1986-02-04	Immunex Corporation	Immediate ligand detection assay
US4626513A (en)	1983-11-10	1986-12-02	Massachusetts General Hospital	Method and apparatus for ligand detection
AU567140B2 (en)	1984-01-06	1987-11-12	Shionogi & Co., Ltd.	Sulphonamido-benzamide derivatives
DE3483099D1 (en)	1984-03-15	1990-10-04	Immunex Corp	TEST FOR IMMEDIATELY DETECTING LIGANDS, TEST SET AND ITS PRODUCTION.
IT1196133B (en)	1984-06-06	1988-11-10	Ausonia Farma Srl	FURANIC DERIVATIVES WITH ANTI-ULCER ACTIVITY
JPS6135946U (en)	1984-07-23	1986-03-05	栄一早乙女	Stake removal for fixing cultivation house
US4714693A (en)	1986-04-03	1987-12-22	Uop Inc.	Method of making a catalyst composition comprising uniform size metal components on carrier
DE3642315A1 (en)	1986-12-11	1988-06-23	Boehringer Mannheim Gmbh	NEW PYRROLOBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
US5688655A (en)	1988-02-10	1997-11-18	Ict Pharmaceuticals, Inc.	Method of screening for protein inhibitors and activators
US6054270A (en)	1988-05-03	2000-04-25	Oxford Gene Technology Limited	Analying polynucleotide sequences
US5700637A (en)	1988-05-03	1997-12-23	Isis Innovation Limited	Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5658775A (en)	1988-05-17	1997-08-19	Sloan-Kettering Institute For Cancer Research	Double copy retroviral vector
JP2528706B2 (en)	1988-05-30	1996-08-28	ゼリア新薬工業株式会社	Pharmaceutical composition of dihydropyridine compound
JP3082204B2 (en)	1988-09-01	2000-08-28	ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ	Recombinant retrovirus with an amphotropic and ecotropic host range
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5800992A (en)	1989-06-07	1998-09-01	Fodor; Stephen P.A.	Method of detecting nucleic acids
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en)	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US5527681A (en)	1989-06-07	1996-06-18	Affymax Technologies N.V.	Immobilized molecular synthesis of systematically substituted compounds
WO1991018088A1 (en)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
DE4022414A1 (en)	1990-07-13	1992-01-16	Bayer Ag	SUBSTITUTED PYRROLO-PYRIDINE
US5958930A (en)	1991-04-08	1999-09-28	Duquesne University Of The Holy Ghost	Pyrrolo pyrimidine and furo pyrimidine derivatives
ATE159426T1 (en)	1991-04-16	1997-11-15	Nippon Shinyaku Co Ltd	METHOD FOR PRODUCING A SOLID DISPERSION
WO1993002556A1 (en)	1991-07-26	1993-02-18	University Of Rochester	Cancer therapy utilizing malignant cells
US5632957A (en)	1993-11-01	1997-05-27	Nanogen	Molecular biological diagnostic systems including electrodes
GB9127531D0 (en)	1991-12-31	1992-02-19	Fujisawa Pharmaceutical Co	Heterocyclic compound
FR2687402B1 (en)	1992-02-14	1995-06-30	Lipha	NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
JPH05236997A (en)	1992-02-28	1993-09-17	Hitachi Ltd	Polynucleotide capture chip
JPH06135946A (en)	1992-10-30	1994-05-17	Otsuka Pharmaceut Co Ltd	Pyrazine derivative
AU686115B2 (en)	1992-11-02	1998-02-05	Fujisawa Pharmaceutical Co., Ltd.	Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
GB9226855D0 (en)	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
ES2134929T3 (en)	1993-03-01	1999-10-16	Merck Sharp & Dohme	PIRROLO-PIRIDINA DERIVATIVES AS LINKS FOR DOPAMINE RECEPTORS.
US5576319A (en)	1993-03-01	1996-11-19	Merck, Sharp & Dohme Ltd.	Pyrrolo-pyridine derivatives
EP0687267B1 (en)	1993-03-01	1999-09-01	MERCK SHARP & DOHME LTD.	Pyrrolo-pyridine derivatives as ligands of dopamine receptor
CN1118598A (en)	1993-03-01	1996-03-13	默克·夏普-道姆公司	Pyrrolopyridine Derivatives
PT705279E (en)	1993-05-27	2003-07-31	Selectide Corp	LIBRARIES IN SOLID PHASE CODIFIED, TOPOLOGICALLY SEGREGATED
US5840485A (en)	1993-05-27	1998-11-24	Selectide Corporation	Topologically segregated, encoded solid phase libraries
IT1265057B1 (en)	1993-08-05	1996-10-28	Dompe Spa	TROPIL 7-AZAINDOLIL-3-CARBOXYAMIDE
US5631236A (en)	1993-08-26	1997-05-20	Baylor College Of Medicine	Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5426039A (en)	1993-09-08	1995-06-20	Bio-Rad Laboratories, Inc.	Direct molecular cloning of primer extended DNA containing an alkane diol
GB9319297D0 (en)	1993-09-17	1993-11-03	Wellcome Found	Indole derivatives
US6045996A (en)	1993-10-26	2000-04-04	Affymetrix, Inc.	Hybridization assays on oligonucleotide arrays
US6468742B2 (en)	1993-11-01	2002-10-22	Nanogen, Inc.	Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5965452A (en)	1996-07-09	1999-10-12	Nanogen, Inc.	Multiplexed active biologic array
US5486525A (en)	1993-12-16	1996-01-23	Abbott Laboratories	Platelet activating factor antagonists: imidazopyridine indoles
US5360882A (en)	1994-02-04	1994-11-01	Isp Investments Inc.	Eutectic compositions of divinyl imidazolidone and vinyl caprolactam
EP1195372A1 (en)	1994-04-18	2002-04-10	Mitsubishi Pharma Corporation	N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9408577D0 (en)	1994-04-29	1994-06-22	Fujisawa Pharmaceutical Co	New compound
US5807522A (en)	1994-06-17	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods for fabricating microarrays of biological samples
GB9412719D0 (en)	1994-06-24	1994-08-17	Erba Carlo Spa	Substituted azaindolylidene compounds and process for their preparation
US5763198A (en)	1994-07-22	1998-06-09	Sugen, Inc.	Screening assays for compounds
WO1996005200A1 (en)	1994-08-10	1996-02-22	Merck Sharp & Dohme Limited	TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO[2,3-b]PYRIDINE
GB9416162D0 (en)	1994-08-10	1994-09-28	Merck Sharp & Dohme	Therapeutic agents
GB9416189D0 (en)	1994-08-10	1994-09-28	Merck Sharp & Dohme	Therapeutic agents
GB9420521D0 (en)	1994-10-12	1994-11-30	Smithkline Beecham Plc	Novel compounds
US5556752A (en)	1994-10-24	1996-09-17	Affymetrix, Inc.	Surface-bound, unimolecular, double-stranded DNA
US5830645A (en)	1994-12-09	1998-11-03	The Regents Of The University Of California	Comparative fluorescence hybridization to nucleic acid arrays
US5837815A (en)	1994-12-15	1998-11-17	Sugen, Inc.	PYK2 related polypeptide products
GB9503400D0 (en)	1995-02-21	1995-04-12	Merck Sharp & Dohme	Therpeutic agents
GB2298199A (en)	1995-02-21	1996-08-28	Merck Sharp & Dohme	Synthesis of azaindoles
US5959098A (en)	1996-04-17	1999-09-28	Affymetrix, Inc.	Substrate preparation process
US6117681A (en)	1995-03-29	2000-09-12	Bavarian Nordic Research Inst. A/S	Pseudotyped retroviral particles
GB9507291D0 (en)	1995-04-07	1995-05-31	Merck Sharp & Dohme	Therapeutic agents
GB2299581A (en)	1995-04-07	1996-10-09	Merck Sharp & Dohme	3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes
GB9511220D0 (en)	1995-06-02	1995-07-26	Glaxo Group Ltd	Solid dispersions
US6110456A (en)	1995-06-07	2000-08-29	Yale University	Oral delivery or adeno-associated viral vectors
US5856174A (en)	1995-06-29	1999-01-05	Affymetrix, Inc.	Integrated nucleic acid diagnostic device
WO1997003967A1 (en)	1995-07-22	1997-02-06	Rhone-Poulenc Rorer Limited	Substituted aromatic compounds and their pharmaceutical use
US5866411A (en)	1995-09-08	1999-02-02	Pedersen; Finn Skou	Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
US5747276A (en)	1995-09-15	1998-05-05	The Scripps Research Institute	Screening methods for the identification of novel antibiotics
US5721118A (en)	1995-10-31	1998-02-24	The Regents Of The University Of California, San Diego	Mammalian artificial chromosomes and methods of using same
US6022963A (en)	1995-12-15	2000-02-08	Affymetrix, Inc.	Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en)	1996-03-11	2000-01-11	Affymetrix, Inc.	Nucleic acid affinity columns
US6025155A (en)	1996-04-10	2000-02-15	Chromos Molecular Systems, Inc.	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5804585A (en)	1996-04-15	1998-09-08	Texas Biotechnology Corporation	Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5908401A (en)	1996-05-08	1999-06-01	The Aps Organization, Llp	Method for iontophoretic delivery of antiviral agents
US5725838A (en)	1996-05-31	1998-03-10	Resolution Pharmaceuticals, Inc.	Radiolabeled D4 receptor ligands
AU3568897A (en)	1996-06-07	1998-01-05	Eos Biotechnology, Inc.	Immobilised linear oligonucleotide arrays
AU3191397A (en)	1996-06-25	1998-01-14	Takeda Chemical Industries Ltd.	Oxazolone derivatives and their use as anti-(helicobacter pylori) agent
EP0956865B2 (en)	1996-08-12	2010-08-18	Mitsubishi Tanabe Pharma Corporation	MEDICINES COMPRISING Rho KINASE INHIBITOR
JPH10130269A (en)	1996-09-04	1998-05-19	Nippon Chemiphar Co Ltd	Carboline derivative
JPH1087629A (en)	1996-09-18	1998-04-07	Fujisawa Pharmaceut Co Ltd	New isoquinoline derivative, and its medicinal use
HUP9903330A2 (en)	1996-11-19	2000-03-28	Amgen Inc.	Aryl and heteroaryl substituted fused pyrrole derivatives, as antiinflammatory agents containing the same
US6294330B1 (en)	1997-01-31	2001-09-25	Odyssey Pharmaceuticals Inc.	Protein fragment complementation assays for the detection of biological or drug interactions
EP0972071A4 (en)	1997-03-07	2004-04-21	Tropix Inc	Protease inhibitor assay
US5977131A (en)	1997-04-09	1999-11-02	Pfizer Inc.	Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
AU7132998A (en)	1997-04-24	1998-11-13	Ortho-Mcneil Corporation, Inc.	Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
US6096718A (en)	1997-06-05	2000-08-01	Gene Targeting Corp.	Tissue specific adenovirus vectors for breast cancer treatment
SG72827A1 (en)	1997-06-23	2000-05-23	Hoffmann La Roche	Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
WO1999000386A1 (en)	1997-06-27	1999-01-07	Resolution Pharmaceuticals Inc.	Dopamine d4 receptor ligands
US6235769B1 (en)	1997-07-03	2001-05-22	Sugen, Inc.	Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6826296B2 (en)	1997-07-25	2004-11-30	Affymetrix, Inc.	Method and system for providing a probe array chip design database
PT901786E (en)	1997-08-11	2007-08-07	Pfizer Prod Inc	Solid pharmaceutical dispersions with enhanced bioavailability
US6161776A (en)	1997-08-12	2000-12-19	Nibco Inc.	Multi-layered, porous mat turf irrigation apparatus and method
AU8908198A (en)	1997-08-15	1999-03-08	Hyseq, Inc.	Methods and compositions for detection or quantification of nucleic acid species
DE69833698T2 (en)	1997-09-11	2006-11-16	Bioventures, Inc., Murfreesboro	Process for the preparation of high density arrays
US6178384B1 (en)	1997-09-29	2001-01-23	The Trustees Of Columbia University In The City Of New York	Method and apparatus for selecting a molecule based on conformational free energy
US6465178B2 (en)	1997-09-30	2002-10-15	Surmodics, Inc.	Target molecule attachment to surfaces
CN100360507C (en)	1997-12-22	2008-01-09	拜尔有限公司	Inhibition of RAF Kinases by Substituted Heterocyclic Ureas
EP1042276B1 (en)	1997-12-23	2004-11-17	Warner-Lambert Company Llc	Thiourea compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
CA2326140A1 (en)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
WO1999051595A1 (en)	1998-04-02	1999-10-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
AU3118399A (en)	1998-04-02	1999-10-25	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
JP2002510630A (en)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	Gonadotropin-releasing hormone antagonist
JP2002510631A (en)	1998-04-02	2002-04-09	メルクエンドカムパニーインコーポレーテッド	Gonadotropin-releasing hormone antagonist
AU3117899A (en)	1998-04-02	1999-10-25	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
AU3463699A (en)	1998-04-03	1999-10-25	Phylos, Inc.	Addressable protein arrays
US6048695A (en)	1998-05-04	2000-04-11	Baylor College Of Medicine	Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
WO1999063929A2 (en)	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
US6113913A (en)	1998-06-26	2000-09-05	Genvec, Inc.	Recombinant adenovirus
AU5198199A (en)	1998-08-17	2000-03-06	Senju Pharmaceutical Co., Ltd.	Preventives/remedies for glaucoma
DK1107973T3 (en)	1998-08-28	2004-02-23	Astrazeneca Ab	New Thieno (2,3-D) Pyrimidinediones, Methods for their Preparation and Use in Therapy
CN1261098C (en)	1998-08-28	2006-06-28	西奥斯股份有限公司	Inhibitors of p38-alpha kinase
US6594527B2 (en)	1998-09-18	2003-07-15	Nexmed Holdings, Inc.	Electrical stimulation apparatus and method
BR9913888A (en)	1998-09-18	2002-01-08	Basf Ag	Compound, and, methods of inhibiting protein kinase activity, treating a patient who has a condition that is mediated by protein kinase activity and decreasing fertility in a patient
US6350786B1 (en)	1998-09-22	2002-02-26	Hoffmann-La Roche Inc.	Stable complexes of poorly soluble compounds in ionic polymers
US6277628B1 (en)	1998-10-02	2001-08-21	Incyte Genomics, Inc.	Linear microarrays
IT1303759B1 (en)	1998-11-17	2001-02-23	Dompe Spa	IMPROVED PROCEDURE FOR THE PREPARATION OF 7-AZAINDOLYL-3-CARBOXYLIC ACID.
US6277489B1 (en)	1998-12-04	2001-08-21	The Regents Of The University Of California	Support for high performance affinity chromatography and other uses
US20010001449A1 (en)	1998-12-30	2001-05-24	Thomas R. Kiliany	Low-pressure hydrocracking process
KR20020009570A (en)	1999-03-05	2002-02-01	도리이 신이찌로	HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE α4β2 RECEPTOR
US6792306B2 (en)	2000-03-10	2004-09-14	Biophoretic Therapeutic Systems, Llc	Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
AU761453B2 (en)	1999-03-17	2003-06-05	Astrazeneca Ab	Amide derivatives
AR028475A1 (en)	1999-04-22	2003-05-14	Wyeth Corp	DERIVATIVES OF AZAINDOL AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION.
US6653309B1 (en)	1999-04-26	2003-11-25	Vertex Pharmaceuticals Incorporated	Inhibitors of IMPDH enzyme technical field of the invention
US6221653B1 (en)	1999-04-27	2001-04-24	Agilent Technologies, Inc.	Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
FR2793793B1 (en)	1999-05-19	2004-02-27	Adir	NOVEL SUBSTITUTED DIMERIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6492406B1 (en)	1999-05-21	2002-12-10	Astrazeneca Ab	Pharmaceutically active compounds
TWI234557B (en)	1999-05-26	2005-06-21	Telik Inc	Novel naphthalene ureas as glucose uptake enhancers
MXPA01012442A (en)	1999-06-03	2004-09-10	Abbott Gmbh & Co Kg	Benzothiazinone and benzoxazinone compounds.
BR0012896A (en)	1999-07-30	2002-06-18	Abbott Gmbh & Co Kg	2-pyrazolin-5-ones
US6653151B2 (en)	1999-07-30	2003-11-25	Large Scale Proteomics Corporation	Dry deposition of materials for microarrays using matrix displacement
WO2001024236A1 (en)	1999-09-27	2001-04-05	Infineon Technologies North America Corp.	Semiconductor structures having a capacitor and manufacturing methods
GB9924962D0 (en)	1999-10-21	1999-12-22	Mrc Collaborative Centre	Allosteric sites on muscarinic receptors
US20010008765A1 (en)	1999-12-06	2001-07-19	Fuji Photo Film Co., Ltd.	DNA chip and reactive solid carrier
ATE299881T1 (en)	1999-12-21	2005-08-15	Sugen Inc	4-SUBSTITUTED 7-AZA-INDOLIN-2-ONE AND THEIR APPLICATION AS PROTEIN KINASE INHIBITORS
AU784266B2 (en)	1999-12-22	2006-03-02	Sugen, Inc.	Indolinone derivatives for modulation of c-kit tyrosine kinase
FR2805259B1 (en)	2000-02-17	2002-03-29	Inst Nat Sante Rech Med	NOVEL N-MERCAPTOACYL AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20020061892A1 (en)	2000-02-22	2002-05-23	Tao Wang	Antiviral azaindole derivatives
JP2001278886A (en)	2000-03-28	2001-10-10	Dai Ichi Seiyaku Co Ltd	Benzoxazine derivative and medicament containing the same
GB0007934D0 (en)	2000-03-31	2000-05-17	Darwin Discovery Ltd	Chemical compounds
US6335342B1 (en)	2000-06-19	2002-01-01	Pharmacia & Upjohn S.P.A.	Azaindole derivatives, process for their preparation, and their use as antitumor agents
ATE423120T1 (en)	2000-06-26	2009-03-15	Pfizer Prod Inc	PYRROLOÄ2,3-DÜPYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE ACTIVES
US6903099B2 (en)	2000-06-26	2005-06-07	Lilly Icos Llc	Condensed pyrazindione derivatives
KR20030027093A (en)	2000-08-31	2003-04-03	화이자 프로덕츠 인크.	Pyrazole Derivatives and Their Use as Protein Kinase Inhibitors
SK10722003A3 (en)	2001-02-27	2004-02-03	Astrazeneca Ab	Pharmaceutical formulation comprising bicalutamide in solid dispersion with an enteric polymer and use thereof
US7109208B2 (en)	2001-04-11	2006-09-19	Senju Pharmaceutical Co., Ltd.	Visual function disorder improving agents
EP1381600A1 (en)	2001-04-24	2004-01-21	Wyeth, A Corporation of the State of Delaware	Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
GB0114417D0 (en)	2001-06-13	2001-08-08	Boc Group Plc	Lubricating systems for regenerative vacuum pumps
EP1267111A1 (en)	2001-06-15	2002-12-18	Dsm N.V.	Pressurized fluid conduit
US20040171630A1 (en)	2001-06-19	2004-09-02	Yuntae Kim	Tyrosine kinase inhibitors
US7291639B2 (en)	2001-06-20	2007-11-06	Wyeth	Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
SE0102300D0 (en)	2001-06-26	2001-06-26	Astrazeneca Ab	Compounds
US20030091974A1 (en)	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
SE0102439D0 (en)	2001-07-05	2001-07-05	Astrazeneca Ab	New compounds
UA75425C2 (en)	2001-07-09	2006-04-17		Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0117583D0 (en)	2001-07-19	2001-09-12	Astrazeneca Ab	Novel compounds
US6858860B2 (en)	2001-07-24	2005-02-22	Seiko Epson Corporation	Apparatus and method for measuring natural period of liquid
GB0118479D0 (en)	2001-07-28	2001-09-19	Astrazeneca Ab	Novel compounds
JP2003073357A (en)	2001-09-03	2003-03-12	Mitsubishi Pharma Corp	Rho kinase inhibitors containing amide compounds
WO2003020698A2 (en)	2001-09-06	2003-03-13	Prochon Biotech Ltd.	Protein tyrosine kinase inhibitors
WO2003028724A1 (en)	2001-10-04	2003-04-10	Smithkline Beecham Corporation	Chk1 kinase inhibitors
WO2003037862A1 (en)	2001-10-30	2003-05-08	Nippon Shinyaku Co., Ltd.	Amide derivatives and drugs
US20030119839A1 (en)	2001-12-13	2003-06-26	Nan-Horng Lin	Protein kinase inhibitors
DE60303009T2 (en)	2002-01-22	2006-07-13	Warner-Lambert Co. Llc	2- (pyridin-2-ylamino) -pyrido [2,3-d] pyrimidine-7-ONE
RU2365588C2 (en)	2002-02-01	2009-08-27	Астразенека Аб	Quinazoline compounds
US20030236277A1 (en)	2002-02-14	2003-12-25	Kadow John F.	Indole, azaindole and related heterocyclic pyrrolidine derivatives
US20040171062A1 (en)	2002-02-28	2004-09-02	Plexxikon, Inc.	Methods for the design of molecular scaffolds and ligands
US6884889B2 (en)	2002-03-25	2005-04-26	Bristol-Myers Squibb Co.	Processes for the preparation of antiviral 7-azaindole derivatives
US7534800B2 (en)	2002-03-28	2009-05-19	Eisai R & D Development Co., Ltd.	7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
DE60331219D1 (en)	2002-03-28	2010-03-25	Eisai R&D Man Co Ltd	AZAINDOLE AS INHIBITORS FROM C-JUN N-TERMINAL KINASEN
AU2003224257A1 (en)	2002-04-09	2003-10-27	Astex Technology Limited	Heterocyclic compounds and their use as modulators of p38 map kinase
UA78999C2 (en)	2002-06-04	2007-05-10	Wyeth Corp	1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
EP1554269A1 (en)	2002-07-09	2005-07-20	Vertex Pharmaceuticals Incorporated	Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
TW200403243A (en)	2002-07-18	2004-03-01	Wyeth Corp	1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
EP1388341A1 (en)	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US6878887B2 (en)	2002-08-07	2005-04-12	Matsushita Electric Industrial Co., Ltd.	Anti-malfunction mechanism for variable output device
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
SE0202463D0 (en)	2002-08-14	2002-08-14	Astrazeneca Ab	Novel compounds
PT1534340E (en)	2002-09-06	2012-03-13	Cerulean Pharma Inc	Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
AU2003272548A1 (en)	2002-09-16	2004-04-30	Plexxikon, Inc.	Crystal structure of pim-1 kinase
US6766199B2 (en)	2002-10-10	2004-07-20	Proventure (Far East), Limited	Skin/hair treatment method and system
US7183241B2 (en)	2002-10-15	2007-02-27	Exxonmobil Research And Engineering Company	Long life lubricating oil composition with very low phosphorus content
GB0226370D0 (en)	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
SE0203654D0 (en)	2002-12-09	2002-12-09	Astrazeneca Ab	New compounds
JP2006511554A (en)	2002-12-13	2006-04-06	スミスクラインビーチャムコーポレーション	Piperidine derivatives as CCR5 antagonists
US7589207B2 (en)	2002-12-13	2009-09-15	Smithkline Beecham Corporation	Cyclohexyl compounds as CCR5 antagonists
UA80171C2 (en)	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
US7696225B2 (en)	2003-01-06	2010-04-13	Osi Pharmaceuticals, Inc.	(2-carboxamido)(3-Amino) thiophene compounds
SE0300119D0 (en)	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
SE0300120D0 (en)	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
US20050085463A1 (en)	2003-01-23	2005-04-21	Weiner David M.	Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050048573A1 (en)	2003-02-03	2005-03-03	Plexxikon, Inc.	PDE5A crystal structure and uses
WO2004069138A2 (en)	2003-02-03	2004-08-19	Novartis Ag	Pharmaceutical formulation
AU2004213375A1 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
SE0300456D0 (en)	2003-02-19	2003-02-19	Astrazeneca Ab	Novel compounds
WO2004078923A2 (en)	2003-02-28	2004-09-16	Plexxikon, Inc.	Pyk2 crystal structure and uses
JP4787150B2 (en)	2003-03-06	2011-10-05	エーザイ・アール・アンド・ディー・マネジメント株式会社	JNK inhibitor
WO2004101565A2 (en)	2003-05-16	2004-11-25	Eisai Co., Ltd.	Jnk inhibitors
US20050079548A1 (en)	2003-07-07	2005-04-14	Plexxikon, Inc.	Ligand development using PDE4B crystal structures
SI1648889T1 (en)	2003-07-11	2009-02-28	Warner Lambert Co	Isethionate salt of a selective cdk4 inhibitor
AU2004259738B2 (en)	2003-07-17	2011-11-17	Plexxikon, Inc.	PPAR active compounds
US7348338B2 (en)	2003-07-17	2008-03-25	Plexxikon, Inc.	PPAR active compounds
CL2004001884A1 (en)	2003-08-04	2005-06-03	Pfizer Prod Inc	DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.
TWI339206B (en)	2003-09-04	2011-03-21	Vertex Pharma	Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en)	2003-09-09	2005-05-19	Temple University-Of The Commonwealth System Of Higher Education	Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
US20050164300A1 (en)	2003-09-15	2005-07-28	Plexxikon, Inc.	Molecular scaffolds for kinase ligand development
WO2005030128A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Pyrazole modulators of metabotropic glutamate receptors
KR100793095B1 (en)	2003-10-01	2008-01-10	주식회사 프로메디텍	Novel sulfonamide derivatives with bace inhibitory activity
BRPI0415210A (en)	2003-10-08	2006-12-05	Irm Llc	compounds and compositions as protein kinase inhibitors
DE10357510A1 (en)	2003-12-09	2005-07-07	Bayer Healthcare Ag	Heteroaryl-substituted benzenes
JP5138938B2 (en)	2003-12-19	2013-02-06	プレキシコンインコーポレーテッド	Compounds and methods for the development of RET modulators
US20070066641A1 (en)	2003-12-19	2007-03-22	Prabha Ibrahim	Compounds and methods for development of RET modulators
US7517970B2 (en)	2003-12-19	2009-04-14	Plexxikon, Inc.	Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
BRPI0417533B1 (en)	2003-12-24	2016-03-01	Danisco	variant enzyme glycolipid acyltransferase, use and method for its production, method for preparing a food product and flour baked product, enzymatic refinement process
GB0330043D0 (en)	2003-12-24	2004-01-28	Pharmacia Italia Spa	Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en)	2003-12-24	2004-01-28	Pharmacia Italia Spa	Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
BRPI0507668A (en)	2004-02-14	2007-07-17	Irm Llc	compounds and compositions as protein kinase inhibitors
GB0403635D0 (en)	2004-02-18	2004-03-24	Devgen Nv	Pyridinocarboxamides with improved activity as kinase inhibitors
GB0405055D0 (en)	2004-03-05	2004-04-07	Eisai London Res Lab Ltd	JNK inhibitors
CA2555914A1 (en)	2004-03-08	2005-09-22	Amgen Inc.	Therapeutic modulation of ppar (gamma) activity
KR20050091462A (en)	2004-03-12	2005-09-15	한국과학기술연구원	Furopyrimidine compound and ddr2 tyrosine kinase activity inhibitor comprising the same
JP4937112B2 (en)	2004-03-30	2012-05-23	バーテックスファーマシューティカルズインコーポレイテッド	Azaindoles useful as inhibitors of JAK and other protein kinases
CN101014597A (en)	2004-04-02	2007-08-08	沃泰克斯药物股份有限公司	Azaindoles useful as inhibitors of rock and other protein kinases
CN101031293A (en)	2004-05-06	2007-09-05	普莱希科公司	Pde4b inhibitors and uses therefor
WO2005115363A2 (en)	2004-05-25	2005-12-08	Yale University	Method for treating skeletal disorders resulting from fgfr malfunction
WO2005116035A1 (en)	2004-05-27	2005-12-08	Pfizer Products Inc.	Pyrrolopyrimidine derivatives useful in cancer treatment
EP1758571A1 (en)	2004-05-29	2007-03-07	7TM Pharma A/S	Crth2 receptor ligands for therapeutic use
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
TW200616632A (en)	2004-06-17	2006-06-01	Plexxikon Inc	Compounds modulating c-kit activity and uses therefor
EP1765819B1 (en)	2004-06-30	2014-03-12	Vertex Pharmaceuticals Inc.	Azaindoles useful as inhibitors of protein kinases
US7140816B2 (en)	2004-07-20	2006-11-28	H&S Tool, Inc.	Multi-functional tube milling head
WO2006015124A2 (en)	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
US7361763B2 (en)	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US7626021B2 (en)	2004-07-27	2009-12-01	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
US7361764B2 (en)	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US7709645B2 (en)	2004-07-27	2010-05-04	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US20060024361A1 (en)	2004-07-28	2006-02-02	Isa Odidi	Disintegrant assisted controlled release technology
WO2006010637A2 (en)	2004-07-30	2006-02-02	Gpc Biotech Ag	Pyridinylamines
CN101048407A (en)	2004-09-03	2007-10-03	普莱希科公司	Bicyclic heteroaryl PDE4B inhibitors
CA2588953A1 (en)	2004-11-30	2006-06-08	Plexxikon, Inc.	Ppar active compounds
WO2006060535A2 (en)	2004-11-30	2006-06-08	Plexxikon, Inc.	Indole derivatives for use as ppar active compounds
WO2006063167A1 (en)	2004-12-08	2006-06-15	Smithkline Beecham Corporation	1h-pyrrolo[2,3-b]pyridines
US20060160135A1 (en)	2004-12-08	2006-07-20	Weiru Wang	SF-1 and LRH-1 modulator development
WO2006114180A1 (en)	2005-04-25	2006-11-02	Merck Patent Gmbh	Novel aza- heterocycles serving as kinase inhibitors
FR2884821B1 (en)	2005-04-26	2007-07-06	Aventis Pharma Sa	SUBSTITUTED PYRROLOPYRIDINES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
CA2608733A1 (en)	2005-05-17	2007-02-01	Plexxikon, Inc.	Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
JP2008545660A (en)	2005-05-20	2008-12-18	バーテックスファーマシューティカルズインコーポレイテッド	Pyrropyridine compounds useful as protein kinase inhibitors
KR20080007376A (en)	2005-05-23	2008-01-18	테바 파마슈티컬 인더스트리즈 리미티드	Amorphous cinacalcet hydrochloride and its preparation
CN101203484B (en)	2005-06-21	2012-09-05	三井化学株式会社	Amide derivative and pesticide containing such compound
KR20080031871A (en)	2005-06-23	2008-04-11	아스트라제네카 아베	Quinoline 3-sulfonate esters as NX3 receptor modulators
DE102005034406A1 (en)	2005-07-22	2007-02-01	Ratiopharm Gmbh	New salts of rosiglitazone
GB0516156D0 (en)	2005-08-05	2005-09-14	Eisai London Res Lab Ltd	JNK inhibitors
US7754717B2 (en)	2005-08-15	2010-07-13	Amgen Inc.	Bis-aryl amide compounds and methods of use
EP1943245A2 (en)	2005-09-07	2008-07-16	Plexxikon, Inc.	1,3-disubstituted indole derivatives for use as ppar modulators
RU2008108221A (en)	2005-09-07	2009-10-20	Плекссикон, Инк. (Us)	COMPOUNDS ACTIVE AGAINST PPAR (RECEPTORS OF ACTIVATORS OF PROLIFERATION BY PEROXISIS)
WO2007030574A2 (en)	2005-09-07	2007-03-15	Plexxikon, Inc.	1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
JP2009530415A (en)	2006-03-20	2009-08-27	バーテックスファーマシューティカルズインコーポレイテッド	Pharmaceutical composition
US7963673B2 (en)	2006-05-30	2011-06-21	Finn Bruce L	Versatile illumination system
DK2848610T3 (en)	2006-11-15	2017-11-06	Ym Biosciences Australia Pty	Inhibitors of kinase activity
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
GB0624084D0 (en)	2006-12-01	2007-01-10	Selamine Ltd	Ramipril amino acid salts
US8093246B2 (en)	2006-12-14	2012-01-10	Lexicon Pharmaceuticals, Inc.	O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
CN101641351A (en)	2006-12-21	2010-02-03	普莱希科公司	Be used for Compounds and methods for and indication thereof that kinases is regulated
PE20090159A1 (en)	2007-03-08	2009-02-21	Plexxikon Inc	INDOL-PROPIONIC ACID DERIVED COMPOUNDS AS PPARs MODULATORS
CN101668737A (en)	2007-03-08	2010-03-10	普莱希科公司	Ppar active compounds
EP2155166A2 (en)	2007-05-11	2010-02-24	F. Hoffmann-Roche AG	Pharmaceutical compositions for poorly soluble drugs
TW200908968A (en)	2007-05-29	2009-03-01	Sgx Pharmaceuticals Inc	Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
SG183036A1 (en)	2007-07-17	2012-08-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
CN101784260A (en)	2007-07-23	2010-07-21	法尔玛赞公司	Pharmaceutical compositions comprising dihydropyridine calcium channel antagonists and processes for their preparation
CA2639416C (en)	2007-09-11	2019-12-31	F. Hoffmann-La Roche Ag	Diagnostic test for susceptibility to b-raf kinase inhibitors
CA2716947A1 (en)	2008-02-29	2009-09-11	Array Biopharma Inc.	Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP2265574A1 (en)	2008-02-29	2010-12-29	Array Biopharma, Inc.	N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
TW200940540A (en)	2008-02-29	2009-10-01	Array Biopharma Inc	RAF inhibitor compounds and methods of use thereof
EP2265610B1 (en)	2008-02-29	2012-12-12	Array Biopharma, Inc.	Pyrazole [3, 4-b]pyridine raf inhibitors
WO2009115084A2 (en)	2008-03-20	2009-09-24	Schebo Biotech Ag	Novel pyrrolopyrimidine derivatives and the use thereof
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
WO2009143018A2 (en)	2008-05-19	2009-11-26	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (en)	2008-05-19	2009-12-16	Plexxikon Inc	PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS
US8110576B2 (en)	2008-06-10	2012-02-07	Plexxikon Inc.	Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
CA2727389A1 (en)	2008-06-10	2009-12-17	Prabha N. Ibrahim	5h-pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
CN102131812B (en)	2008-08-20	2014-04-09	硕腾有限责任公司	Pyrrolo[2,3-d]pyrimidine compounds
WO2010059658A1 (en)	2008-11-20	2010-05-27	Glaxosmithkline Llc	Chemical compounds
CA2755197A1 (en)	2009-03-11	2010-09-16	Plexxikon, Inc.	Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
WO2010111527A1 (en)	2009-03-26	2010-09-30	Plexxikon, Inc.	Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
CN102361870B (en)	2009-04-03	2015-11-25	豪夫迈罗氏公司	Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}- Amide compositions and uses thereof
SG175877A1 (en)	2009-05-04	2011-12-29	Plexxikon Inc	Compounds and methods for inhibition of renin, and indications therefor
MX2012005284A (en)	2009-11-06	2012-06-28	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor.
TWI619713B (en)	2010-04-21	2018-04-01	普雷辛肯公司	Compounds and methods for kinase regulation and their indications
US8779150B2 (en) *	2010-07-21	2014-07-15	Hoffmann-La Roche Inc.	Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
US8709419B2 (en) *	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
FR2964757B1 (en)	2010-09-09	2013-04-05	Giroptic	OPTICAL DEVICE FOR CAPTURING IMAGES ACCORDING TO A 360 ° FIELD
US8642606B2 (en)	2010-09-29	2014-02-04	Plexxikon Inc.	ZAP-70 active compounds
JP5941069B2 (en)	2011-02-07	2016-06-29	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	Compounds and methods for kinase regulation and indications therefor
TWI558702B (en)	2011-02-21	2016-11-21	普雷辛肯公司	Solid forms of a pharmaceutically active substance
CN103917235A (en)	2011-05-17	2014-07-09	普莱希科公司	Kinase modulation and indications therefor
US20130172375A1 (en)	2011-12-13	2013-07-04	Hoffmann-La Roche Inc.	Pharmaceutical composition
US9460029B2 (en)	2012-03-02	2016-10-04	Microsoft Technology Licensing, Llc	Pressure sensitive keys
US9358235B2 (en)	2012-03-19	2016-06-07	Plexxikon Inc.	Kinase modulation, and indications therefor
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
CA2883894C (en)	2012-09-06	2020-08-18	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
RS57117B1 (en)	2012-12-21	2018-06-29	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
SG11201506687RA (en)	2013-03-15	2015-09-29	Plexxikon Inc	Heterocyclic compounds and uses thereof
US20140303121A1 (en)	2013-03-15	2014-10-09	Plexxikon Inc.	Heterocyclic compounds and uses thereof
RU2015149937A (en)	2013-05-30	2017-07-06	Плексксикон Инк.	COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
WO2015134536A1 (en)	2014-03-04	2015-09-11	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
JP6832846B2 (en)	2014-09-15	2021-02-24	プレキシコンインコーポレーテッドＰｌｅｘｘｉｋｏｎＩｎｃ．	Heterocyclic compounds and their uses
WO2016164641A1 (en)	2015-04-08	2016-10-13	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
MX386963B (en)	2015-05-06	2025-03-19	Daiichi Sankyo Inc	SOLID FORMS OF KINASES THAT MODULATE A COMPOUND.
CN107531706A (en)	2015-05-06	2018-01-02	普莱希科公司	Synthesis of Kinase-Regulating 1H-Pyrrolo[2,3-b]pyridine Derivatives
ES2825202T3 (en)	2015-05-22	2021-05-14	Plexxikon Inc	Synthesis of heterocyclic compounds
CA2986739C (en)	2015-05-22	2023-03-14	Plexxikon Inc.	Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
WO2017019804A2 (en)	2015-07-28	2017-02-02	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
MY195977A (en)	2015-09-21	2023-02-27	Plexxikon Inc	Heterocyclic Compounds and uses Thereof
SG11201804711RA (en)	2015-12-07	2018-07-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en)	2016-03-16	2018-12-25	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
TW201815766A (en)	2016-09-22	2018-05-01	美商普雷辛肯公司	Compounds and methods for IDO and TDO modulation, and indications therefor
CA3047580A1 (en)	2016-12-23	2018-07-26	Plexxikon Inc.	Compounds and methods for cdk8 modulation and indications therefor
US10577366B2 (en)	2017-03-20	2020-03-03	Plexxikon Inc.	Crystalline forms of a compound that inhibits bromodomain
US10428067B2 (en)	2017-06-07	2019-10-01	Plexxikon Inc.	Compounds and methods for kinase modulation
US10435404B2 (en)	2017-07-25	2019-10-08	Plexxikon Inc.	Formulations of a compound modulating kinases
WO2019075243A1 (en)	2017-10-13	2019-04-18	Plexxikon Inc.	Solid forms of a compound for modulating kinases
AU2018354423B2 (en)	2017-10-27	2024-11-07	Plexxikon Inc.	Formulations of a compound modulating kinases
CA3094336A1 (en)	2018-03-20	2019-09-26	Plexxikon Inc.	Compounds and methods for ido and tdo modulation, and indications therefor
JP7636646B2 (en)	2019-04-09	2025-02-27	オプナバイオソシエテアノニム	Condensed azines and their applications for the modulation of EP300 or CBP
WO2021113625A1 (en)	2019-12-06	2021-06-10	Plexxikon Inc.	Compounds and methods for cd73 modulation and indications therefor
WO2021202900A1 (en)	2020-04-02	2021-10-07	Plexxikon Inc.	1,6-naphthyridine compounds and methods for csk modulation and indications therefor
AU2021261383A1 (en)	2020-04-23	2022-11-17	Opna Bio SA	Compounds and methods for CD73 modulation and indications therefor
TW202227068A (en)	2020-08-21	2022-07-16	美商普雷辛肯公司	Combinational drug therapies
US20230081426A1 (en)	2020-09-18	2023-03-16	Plexxikon Inc.	Compounds and methods for kras modulation and indications therefor

2012
- 2012-02-01 JP JP2013552610A patent/JP5941069B2/en active Active
- 2012-02-01 PL PL12745360T patent/PL2672967T3/en unknown
- 2012-02-01 CN CN201280017017.7A patent/CN103517710B/en active Active
- 2012-02-01 DK DK12745360.3T patent/DK2672967T3/en active
- 2012-02-01 SG SG2013060397A patent/SG192686A1/en unknown
- 2012-02-01 PE PE2013001837A patent/PE20141360A1/en active IP Right Grant
- 2012-02-01 HU HUE12745360A patent/HUE040136T2/en unknown
- 2012-02-01 AU AU2012214762A patent/AU2012214762B2/en active Active
- 2012-02-01 EP EP12745360.3A patent/EP2672967B1/en active Active
- 2012-02-01 SM SM20190112T patent/SMT201900112T1/en unknown
- 2012-02-01 WO PCT/US2012/023543 patent/WO2012109075A1/en not_active Ceased
- 2012-02-01 US US13/820,734 patent/US9624213B2/en active Active
- 2012-02-01 HR HRP20181779TT patent/HRP20181779T1/en unknown
- 2012-02-01 KR KR1020137023640A patent/KR101911972B1/en active Active
- 2012-02-01 MY MYPI2013002940A patent/MY162950A/en unknown
- 2012-02-01 SI SI201231458T patent/SI2672967T1/en unknown
- 2012-02-01 TR TR2018/16421T patent/TR201816421T4/en unknown
- 2012-02-01 MX MX2013009068A patent/MX358128B/en active IP Right Grant
- 2012-02-01 CA CA2826123A patent/CA2826123C/en active Active
- 2012-02-01 ES ES12745360T patent/ES2696023T3/en active Active
- 2012-02-01 BR BR112013020041-3A patent/BR112013020041B1/en active IP Right Grant
- 2012-02-01 RS RS20181464A patent/RS58455B1/en unknown
- 2012-02-01 PT PT12745360T patent/PT2672967T/en unknown
- 2012-02-01 EA EA201391019A patent/EA028821B9/en not_active IP Right Cessation
- 2012-02-01 LT LTEP12745360.3T patent/LT2672967T/en unknown
- 2012-02-01 MA MA36213A patent/MA34948B1/en unknown
- 2012-02-01 PH PH1/2013/501633A patent/PH12013501633B1/en unknown
- 2012-02-06 TW TW101103734A patent/TWI640521B/en active
- 2012-02-07 AR ARP120100389A patent/AR085316A1/en not_active Application Discontinuation
- 2012-02-07 UY UY0001033899A patent/UY33899A/en active IP Right Grant
2013
- 2013-07-29 IL IL227698A patent/IL227698B/en active IP Right Grant
- 2013-07-31 CR CR20130374A patent/CR20130374A/en unknown
- 2013-08-02 CL CL2013002228A patent/CL2013002228A1/en unknown
- 2013-08-02 ZA ZA2013/05856A patent/ZA201305856B/en unknown
- 2013-08-06 CO CO13187418A patent/CO6781514A2/en unknown
- 2013-09-06 EC ECSP13012869 patent/ECSP13012869A/en unknown
2016
- 2016-02-26 JP JP2016035939A patent/JP2016138119A/en not_active Withdrawn
2017
- 2017-02-17 US US15/435,569 patent/US11337976B2/en active Active
- 2017-04-14 JP JP2017080199A patent/JP6359720B2/en not_active Expired - Fee Related
2019
- 2019-01-16 CY CY20191100052T patent/CY1121511T1/en unknown
2022
- 2022-08-25 US US17/895,972 patent/US12076322B2/en active Active
2024
- 2024-07-19 US US18/778,765 patent/US20250195516A1/en active Pending

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007002325A1 (en) *	2005-06-22	2007-01-04	Plexxikon, Inc.	Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
WO2008079909A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008079903A1 (en) *	2006-12-21	2008-07-03	Plexxikon, Inc.	Pyrrolo [2, 3-b] pyridine derivatives as kinase modulators
WO2010104945A1 (en) *	2009-03-11	2010-09-16	Plexxikon, Inc.	Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
WO2010129567A1 (en) *	2009-05-06	2010-11-11	Plexxikon, Inc.	Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase
WO2011015522A2 (en) *	2009-08-03	2011-02-10	F. Hoffmann-La Roche Ag	Process for the manufacture of pharmaceutically active compounds
WO2011060216A1 (en) *	2009-11-12	2011-05-19	Concert Pharmaceuticals Inc.	Substituted azaindoles
WO2011063159A1 (en) *	2009-11-18	2011-05-26	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
WO2011079133A2 (en) *	2009-12-23	2011-06-30	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
WO2012037060A1 (en) *	2010-09-13	2012-03-22	Concert Pharmaceuticals Inc.	Substituted azaindoles
WO2012138809A1 (en) *	2011-04-05	2012-10-11	Dawei Zhang	Heterocyclic compounds as kinase inhibitors

Also Published As

Publication number	Publication date
ES2696023T3 (en)	2019-01-11
NZ613786A (en)	2015-09-25
AU2012214762B2 (en)	2015-08-13
CY1121511T1 (en)	2020-05-29
MX2013009068A (en)	2013-12-16
CR20130374A (en)	2013-11-18
MX358128B (en)	2018-08-06
LT2672967T (en)	2018-12-10
TWI640521B (en)	2018-11-11
US9624213B2 (en)	2017-04-18
RS58455B1 (en)	2019-04-30
PT2672967T (en)	2018-12-07
KR101911972B1 (en)	2018-10-25
HUE040136T2 (en)	2019-02-28
UY33899A (en)	2012-09-28
AR085316A1 (en)	2013-09-25
US20250195516A1 (en)	2025-06-19
EA028821B9 (en)	2018-10-31
AU2012214762A1 (en)	2013-04-11
JP5941069B2 (en)	2016-06-29
PL2672967T3 (en)	2019-04-30
DK2672967T3 (en)	2019-01-02
EA201391019A1 (en)	2014-01-30
EP2672967A1 (en)	2013-12-18
JP2017160224A (en)	2017-09-14
SMT201900112T1 (en)	2019-02-28
CL2013002228A1 (en)	2014-03-07
BR112013020041B1 (en)	2021-11-23
SG192686A1 (en)	2013-09-30
US11337976B2 (en)	2022-05-24
PH12013501633B1 (en)	2023-10-04
CA2826123C (en)	2016-08-09
US20170157120A1 (en)	2017-06-08
CN103517710B (en)	2017-05-31
JP6359720B2 (en)	2018-07-18
IL227698A0 (en)	2013-09-30
TR201816421T4 (en)	2018-11-21
HRP20181779T1 (en)	2018-12-28
TW201309693A (en)	2013-03-01
CA2826123A1 (en)	2012-08-16
EA028821B1 (en)	2018-01-31
PH12013501633A1 (en)	2014-01-06
CN103517710A (en)	2014-01-15
US20140128373A1 (en)	2014-05-08
IL227698B (en)	2018-01-31
KR20140064712A (en)	2014-05-28
BR112013020041A2 (en)	2016-10-25
SI2672967T1 (en)	2018-12-31
PE20141360A1 (en)	2014-10-13
JP2016138119A (en)	2016-08-04
MY162950A (en)	2017-07-31
US20230277534A1 (en)	2023-09-07
ZA201305856B (en)	2021-05-26
WO2012109075A1 (en)	2012-08-16
JP2014504640A (en)	2014-02-24
CO6781514A2 (en)	2013-10-31
MA34948B1 (en)	2014-03-01
EP2672967B1 (en)	2018-10-17
US12076322B2 (en)	2024-09-03
ECSP13012869A (en)	2013-12-31

Publication	Publication Date	Title
EP2672967A4 (en)	2014-08-20	COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF
HUE036739T2 (en)	2018-07-30	Compounds and methods for kinase modulation and their indications
DK2906696T3 (en)	2019-11-25	METHODS FOR MODULATING C9ORF72 EXPRESSION
EP2892534B8 (en)	2021-09-15	Compounds and methods for kinase modulation, and indications therefor
ZA201407580B (en)	2020-05-27	Compounds and methods for kinase modulation ,and indicationds therefor
HUE036461T2 (en)	2018-07-30	Compounds and Methods for Kinase Modulation and Indications
DK2773635T3 (en)	2017-11-06	Compounds and compositions for modulating EGFR activity
BR112014030155A2 (en)	2017-11-21	harq-ack handling for unintentional downlink subframes.
EP2878646A4 (en)	2016-08-10	LUMINOPHORE LEAF
HUE042952T2 (en)	2019-07-29	Improved interference measurement procedure for channel state information (CSI) feedback
LT3406251T (en)	2024-02-12	PYRUVATKINASE ACTIVATORS FOR USED THERAPY
DK2925636T3 (en)	2019-09-02	CONTAINER CONTAINER FOR ADHESIVES
DK2922955T3 (en)	2019-05-13	Compositions and Methods for Modulating FGFR3 Expression
LT3395357T (en)	2019-08-26	COMPOSITION FOR CONTROLLED OVEN STIMULATION
EP2671878A4 (en)	2014-07-23	SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
FI20126292L (en)	2014-06-13	Method for making glassine paper
EP2726153A4 (en)	2015-01-14	METHODS FOR MODULATING KALLICREIN EXPRESSION (KLKB1)
EP2879675A4 (en)	2016-05-25	COMPOUNDS AND METHODS FOR TARGETING HSP90
EP2547367A4 (en)	2016-02-24	ENHANCED RELEASE SYSTEM FOR GENE MODULATION COMPOUNDS
EP2802565A4 (en)	2015-07-08	COMPOUNDS, COMPOSITIONS AND RELATED METHODS COMPRISING 3-ARYL-QUINOLINES
HK40104784A (en)	2024-08-02	Compounds and methods for kinase modulation, and indications therefor

Legal Events

Date	Code	Title	Description
2013-11-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-12-18	17P	Request for examination filed	Effective date: 20130909
2013-12-18	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-12-18	AX	Request for extension of the european patent	Extension state: BA ME
2014-08-20	A4	Supplementary search report drawn up and despatched	Effective date: 20140723
2014-08-20	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/437 20060101ALI20140717BHEP Ipc: C07D 471/04 20060101AFI20140717BHEP Ipc: A61K 31/5377 20060101ALI20140717BHEP Ipc: A61K 31/506 20060101ALI20140717BHEP
2015-07-29	17Q	First examination report despatched	Effective date: 20150630
2017-04-05	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: PLEXXIKON INC.
2018-05-06	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-05-30	INTG	Intention to grant announced	Effective date: 20180507
2018-08-01	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-08-04	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2018-08-04	GRAL	Information related to payment of fee for publishing/printing deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR3
2018-09-07	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2018-09-07	GRAR	Information related to intention to grant a patent recorded	Free format text: ORIGINAL CODE: EPIDOSNIGR71
2018-09-12	INTC	Intention to grant announced (deleted)
2018-09-14	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-10-17	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-10-17	AX	Request for extension of the european patent	Extension state: BA ME
2018-10-17	INTG	Intention to grant announced	Effective date: 20180907
2018-10-17	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-10-29	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20181779 Country of ref document: HR
2018-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: RENTSCH PARTNER AG, CH Ref country code: CH Ref legal event code: EP
2018-11-14	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-11-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1053877 Country of ref document: AT Kind code of ref document: T Effective date: 20181115 Ref country code: DE Ref legal event code: R096 Ref document number: 602012052324 Country of ref document: DE
2018-11-26	REG	Reference to a national code	Ref country code: RO Ref legal event code: EPE
2018-12-07	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 2672967 Country of ref document: PT Date of ref document: 20181207 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20181130
2018-12-10	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20181017
2018-12-19	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2018-12-28	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20181779 Country of ref document: HR
2019-01-02	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR Ref country code: DK Ref legal event code: T3 Effective date: 20181217
2019-01-11	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2696023 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190111
2019-02-15	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E016621 Country of ref document: EE Effective date: 20181218
2019-02-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E040136 Country of ref document: HU
2019-04-24	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20190400189 Country of ref document: GR Effective date: 20190422
2019-05-17	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20190502 Year of fee payment: 8
2019-07-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602012052324 Country of ref document: DE
2019-08-23	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-08-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-09-25	26N	No opposition filed	Effective date: 20190718
2020-02-07	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20200121 Year of fee payment: 9
2021-02-05	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20210120 Year of fee payment: 10
2021-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 1053877 Country of ref document: AT Kind code of ref document: T Effective date: 20181017
2022-02-04	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20220118 Year of fee payment: 11
2023-02-03	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20230119 Year of fee payment: 12
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230527
2024-02-02	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20240118 Year of fee payment: 13
2025-02-14	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20181779 Country of ref document: HR Payment date: 20250120 Year of fee payment: 14
2025-03-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20250227 Year of fee payment: 14 Ref country code: LU Payment date: 20250227 Year of fee payment: 14
2025-03-27	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20250130 Year of fee payment: 14
2025-04-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20250129 Year of fee payment: 14
2025-04-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20250120 Year of fee payment: 14 Ref country code: DE Payment date: 20250227 Year of fee payment: 14 Ref country code: IS Payment date: 20250120 Year of fee payment: 14 Ref country code: HR Payment date: 20250120 Year of fee payment: 14
2025-04-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20250225 Year of fee payment: 14 Ref country code: RO Payment date: 20250123 Year of fee payment: 14 Ref country code: FI Payment date: 20250225 Year of fee payment: 14 Ref country code: SM Payment date: 20250128 Year of fee payment: 14 Ref country code: LT Payment date: 20250120 Year of fee payment: 14
2025-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BG Payment date: 20250212 Year of fee payment: 14
2025-04-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250303 Year of fee payment: 14
2025-04-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20250227 Year of fee payment: 14 Ref country code: SE Payment date: 20250227 Year of fee payment: 14
2025-04-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NO Payment date: 20250227 Year of fee payment: 14
2025-04-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20250121 Year of fee payment: 14 Ref country code: SI Payment date: 20250117 Year of fee payment: 14 Ref country code: LV Payment date: 20250120 Year of fee payment: 14 Ref country code: CH Payment date: 20250304 Year of fee payment: 14 Ref country code: BE Payment date: 20250227 Year of fee payment: 14 Ref country code: GR Payment date: 20250226 Year of fee payment: 14 Ref country code: EE Payment date: 20250120 Year of fee payment: 14
2025-04-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250225 Year of fee payment: 14 Ref country code: PL Payment date: 20250122 Year of fee payment: 14 Ref country code: CZ Payment date: 20250121 Year of fee payment: 14
2025-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SK Payment date: 20250120 Year of fee payment: 14 Ref country code: IT Payment date: 20250220 Year of fee payment: 14 Ref country code: GB Payment date: 20250227 Year of fee payment: 14
2025-04-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RS Payment date: 20250120 Year of fee payment: 14
2025-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20250130 Year of fee payment: 14 Ref country code: MT Payment date: 20250120 Year of fee payment: 14
2025-05-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AL Payment date: 20250205 Year of fee payment: 14
2025-10-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20250122 Year of fee payment: 14
2025-11-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MK Payment date: 20250122 Year of fee payment: 14